Relative Viability vs Cell Death in Cancer Drug Testing
2026-10-05
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent drug responses. This framework helps researchers interpret apoptosis-focused studies more carefully, particularly when comparing endpoint assays, response timing, and mechanistic claims.
p-tau Ser356 and NUAK Inhibition in Alzheimer’s
2026-10-04
Taylor and colleagues characterize p-tau Ser356 as a pathology-associated tau species that increases with Alzheimer’s disease stage and is frequently present in neurofibrillary tangles. Their cross-species slice culture work shows that NUAK inhibition produces different molecular responses in postnatal mouse and adult human brain tissue, highlighting both the promise and the translational limits of pharmacologically targeting this pathway.
Why (R)-MG132 Matters for Translational Mechanisms
2026-10-03
Translational cancer research increasingly depends on controls that separate pathway-specific biology from chemical stress and altered protein turnover. This article positions (R)-MG132, the functionally weak MG-132 enantiomer, as a conceptual negative control for proteasome inhibition validation while examining what the HNRNPU–PHGDH cervical cancer study does—and does not—establish about proteasome-dependent mechanisms.
CLCC1 and Herpesvirus Nuclear Egress
2026-10-02
A 2024 bioRxiv preprint identifies the host protein CLCC1 as an essential factor in the membrane-fusion step of herpes simplex virus 1 nuclear egress. Genome-wide CRISPR screening and cell-biological analyses connect CLCC1 loss with perinuclear capsid accumulation, reduced viral titers, and defective nuclear pore insertion, providing a framework for studying herpesvirus membrane remodeling.
Cy5-UTP and the Next Generation of RNA Translation
2026-10-01
Cy5-UTP can turn RNA manufacturing into a more observable, decision-ready workflow. This thought-leadership article connects direct fluorescent RNA labeling with circRNA neoantigen vaccine development, while distinguishing analytical utility from clinical readiness.
GSK343: A Practical EZH2 Inhibitor Workflow
2026-10-01
GSK343 provides a cell-permeable, SAM-competitive route to test how EZH2-driven H3K27me3 repression shapes cancer-cell phenotypes. This workflow connects biochemical potency with cell-based chromatin validation, while separating canonical EZH2 effects from the noncanonical CBX2 immune-evasion mechanism highlighted in recent research.
Entecavir (BMS200475): HBV Evidence & Workflow
2026-09-30
Entecavir, also known as BMS200475, is a potent, selective HBV DNA polymerase inhibitor for chronic hepatitis B infection therapy and laboratory replication assays. Its nanomolar cellular activity, activity against selected lamivudine-resistant strains, and high resistance barrier support carefully controlled antiviral workflows, but replication suppression does not equal cccDNA eradication.
L-Phenylephrine: Reliable Cell Assay Workflows
2026-09-30
Learn how L-Phenylephrine (SKU C3021) can improve interpretation of adrenergic cell-viability, apoptosis, and proliferation assays. This scenario-based guide connects α1A receptor pharmacology with practical controls, solution handling, data interpretation, and evidence-based product selection.
Machine Learning for Senolytic Discovery
2026-09-29
The Nature Communications study developed a cost-effective machine-learning workflow trained only on published screening data to identify senolytic candidates. Computational prioritization followed by human-cell validation identified ginkgetin, periplocin, and oleandrin, demonstrating how small and heterogeneous datasets can support early drug discovery while highlighting the need for rigorous selectivity and toxicity testing.
SLC2A5 Fructose Metabolism in Primary CNS Lymphoma
2026-09-29
This Advanced Science study uses single-cell RNA and B-cell receptor profiling to link the glucose-poor, hypoxic primary CNS lymphoma microenvironment with SLC2A5-mediated fructose metabolism. Genetic and pharmacologic experiments identify SLC2A5 as a potential metabolic vulnerability in lymphoma cells and tumor-supportive macrophages, while suggesting tissue-level validation strategies.
Doxycycline (BA1003): Mechanism and Research Use
2026-09-28
Doxycycline is a tetracycline antibiotic used as an antimicrobial agent for research and as a tool for studying metalloproteinase inhibition. This article separates established product properties from preclinical cancer-research context and clarifies that a cited MMP-2-responsive delivery study tested doxorubicin, not doxycycline.
Fenipentol: From Chuanxiong Chemistry to Translation
2026-09-27
Fenipentol links the chemistry of Ligusticum chuanxiong with two research opportunities: examining tissue-specific natural-product networks and probing digestive secretion. Here we separate mechanistic clues from validated effects and outline a cautious path for translational studies.
Calcitriol and the Endometrial VDR–Estrogen Axis
2026-09-26
Calcitriol, or 1,25-dihydroxy vitamin D3, may shape endometrial decidualization through vitamin D receptor signaling and estrogen metabolism. This article unpacks the evidence and translates it into practical assay decisions without confusing cell-model findings with clinical outcomes.
FITC Goat Anti-Rabbit IgG (H+L) Antibody
2026-09-26
Turn rabbit primary-antibody staining into green fluorescent evidence for mapping the testicular ROS/p38/TORC2/CREB findings in the lycopene–T-2 toxin study. This guide distinguishes practical starting conditions for microscopy and flow cytometry from the paper’s reported results, with controls and troubleshooting to help limit background.
Ruxolitinib Links STAT3 to Mitochondrial Cell Death
2026-09-25
A 2024 study connects JAK1/2–STAT3 activity with DRP1-mediated mitochondrial fission in anaplastic thyroid carcinoma (ATC). Its preclinical findings suggest that ruxolitinib suppresses STAT3-dependent DRP1 transcription and promotes caspase-associated apoptosis and GSDME-mediated pyroptosis, identifying a mechanism for further investigation rather than establishing clinical efficacy.